InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.370 0.005 (1.33%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$113 Recce moves closer to clinical study application 19 May 2017 1:31PM $0.200 $0.370 risen by 85%
$113 Appendic 4G 16 May 2017 4:51PM $0.200 $0.370 risen by 85%
$113 Appendix 4C - quarterly 28 Apr 2017 6:46PM $0.205 $0.370 risen by 80.49%
$113 Recce calls for Australian investment in R&D to develop new 19 Apr 2017 2:49PM $0.195 $0.370 risen by 89.74%
$113 Operational Update 10 Apr 2017 8:26AM $0.220 $0.370 risen by 68.18%
$113 Data from large animal study shows RECCE 327 well tolerated 27 Mar 2017 8:27AM $0.240 $0.370 risen by 54.17%
$113 Ceasing to be a substantial holder 15 Mar 2017 4:10PM $0.260 $0.370 risen by 42.31%
$113 Ceasing to be a substantial holder 15 Mar 2017 3:05PM $0.260 $0.370 risen by 42.31%
$113 Change of Director's Interest Notice 9 Mar 2017 4:29PM $0.250 $0.370 risen by 48%
$113 Appendix 4D and Interim Financial Statements 28 Feb 2017 6:32PM $0.255 $0.370 risen by 45.10%
$113 Microscopy Images of its Synthetic Antibiotic in Action Dest 24 Feb 2017 10:01AM $0.240 $0.370 risen by 54.17%
$113 Recce to suspend anti-cancer program 23 Feb 2017 10:00AM $0.230 $0.370 risen by 60.87%
$113 Ceasing to be a substantial holder 7 Feb 2017 6:32PM $0.250 $0.370 risen by 48%
$113 Operational Update and Quarterly Cash Flow 30 Jan 2017 3:36PM $0.230 $0.370 risen by 60.87%
$113 Director Appointment/Resignation 23 Jan 2017 8:24AM $0.210 $0.370 risen by 76.19%
$113 Response to ASX Price Query 18 Jan 2017 9:48AM $0.295 $0.370 risen by 25.42%
$113 Lead compound reduces illness in mice infected by E.coli 18 Jan 2017 9:46AM $0.295 $0.370 risen by 25.42%
$113 Change of Director's Interest Notice 16 Jan 2017 7:46PM $0.295 $0.370 risen by 25.42%
$113 Appendix 3B 16 Jan 2017 7:39PM $0.295 $0.370 risen by 25.42%
$113 Request for Trading Halt 16 Jan 2017 6:04PM $0.295 $0.370 risen by 25.42%
$113 Trading Halt 16 Jan 2017 12:55AM $0.295 $0.370 risen by 25.42%
$113 Encouraging anti-viral activity for lead compound RECCE 327 20 Dec 2016 1:50PM $0.180 $0.370 risen by 105.56%
$113 Appendix 3B 25 Nov 2016 4:47PM $0.160 $0.370 risen by 131.25%
$113 Results of Meeting 23 Nov 2016 8:29AM $0.160 $0.370 risen by 131.25%
$113 AGM Presentation 22 Nov 2016 10:57AM $0.160 $0.370 risen by 131.25%

626 - 650 of 724 results

Page 26 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.